Eighty-two percent (82%) of patients with epilepsy experience rapid heart rate increase associated with a seizure.2
How AspireSR works:
Detects rapid heart rate rise
Delivers automatic stimulation
Has customizable parameters to meet patients' needs
Works in conjuction with Normal and Magnet Mode
In AspireSR clinical trials, over 60% of seizures treated (n=46) ended during auto stimulation.3 For seizures that ended during stimulation (n=28), the closer stimulation was to seizure onset, the shorter the seizure duration.3
*Individual study patient example. Results may vary.
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications.
Talk to your doctor to find out if VNS Therapy might be right for you.
Safety and Tolerability
AspireSR has demonstrated safety and tolerability comparable to currently available VNS Therapy
Proven safe and tolerable, without pharmacological burden
No unanticipated adverse effects
Well-tolerated surgical implantation
The AutoStim Mode is not recommended for patients being treated for cardiac arrhythmia or with a history of bradycardia.
Important Safety Information Incidence of adverse events following stimulation (>5%) were dysphonia, convulsion, headache, oropharyngeal pain, depression, dysphagia, dyspnea, dyspnea exertional, stress, and vomiting.
Contact Cyberonics for more information, 800-332-1375
1. Nevalainen O, et al. Neurology. 2014 Nov 18;83(21):1968-1977. 2. Eggleston KS, et al. Seizure. 2014 Aug;23(7):496-505. 3. Data on file, Cyberonics Inc. Houston, TX.